A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis

OBJECTIVE: The objective of this paper is to assess, in individuals with clinically stable multiple sclerosis (MS), the safety, tolerability, pharmacokinetics (PK) and exploratory pharmacodynamics of the monoclonal recombinant human antibody IgM22 (rHIgM22). METHODS: Seventy-two adults with stable M...

Descripción completa

Detalles Bibliográficos
Autores principales: Eisen, Andrew, Greenberg, Benjamin M, Bowen, James D, Arnold, Douglas L, Caggiano, Anthony O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768281/
https://www.ncbi.nlm.nih.gov/pubmed/29348926
http://dx.doi.org/10.1177/2055217317743097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768281/
https://www.ncbi.nlm.nih.gov/pubmed/29348926
http://dx.doi.org/10.1177/2055217317743097

Ejemplares similares